Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma
Tanya M. Laidlaw, Claus Bachert, Nikhil Amin, et al.
Annals of Allergy Asthma & Immunology (2021) Vol. 126, Iss. 5, pp. 584-592.e1
Open Access | Times Cited: 85

Showing 1-25 of 85 citing articles:

Obesity alters pathology and treatment response in inflammatory disease
Sagar P. Bapat, Caroline Whitty, Cody T. Mowery, et al.
Nature (2022) Vol. 604, Iss. 7905, pp. 337-342
Open Access | Times Cited: 170
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis
Paul Oykhman, Fernando Aleman Paramo, Jean Bousquet, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 4, pp. 1286-1295
Open Access | Times Cited: 160
Chronic Rhinosinusitis With Nasal Polyps: Quality of Life in the Biologics Era
Joaquim Mullol, Antoine Azar, Kathleen M. Buchheit, et al.
The Journal of Allergy and Clinical Immunology In Practice (2022) Vol. 10, Iss. 6, pp. 1434-1453.e9
Open Access | Times Cited: 91
Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric observational Phase IV real‐life study (DUPIREAL)
Eugenio De Corso, Ernesto Pasquini, Matteo Trimarchi, et al.
Allergy (2023) Vol. 78, Iss. 10, pp. 2669-2683
Open Access | Times Cited: 77
Olfactory Outcomes With Dupilumab in Chronic Rhinosinusitis With Nasal Polyps
Joaquim Mullol, Claus Bachert, Nikhil Amin, et al.
The Journal of Allergy and Clinical Immunology In Practice (2021) Vol. 10, Iss. 4, pp. 1086-1095.e5
Open Access | Times Cited: 74
New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis
Ilja Střı́ž, Korneliusz Golebski, Zuzana Střížová, et al.
Clinical Science (2023) Vol. 137, Iss. 9, pp. 727-753
Open Access | Times Cited: 33
A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics
Ulrike Förster‐Ruhrmann, Dafni Stergioudi, Agnieszka J. Szczepek, et al.
World Allergy Organization Journal (2023) Vol. 16, Iss. 2, pp. 100746-100746
Open Access | Times Cited: 28
Tezepelumab Efficacy in Patients with Severe, Uncontrolled Asthma with Comorbid Nasal Polyps in NAVIGATOR
Tanya M. Laidlaw, Andrew Menzies‐Gow, Scott Caveney, et al.
Journal of Asthma and Allergy (2023) Vol. Volume 16, pp. 915-932
Open Access | Times Cited: 27
Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
Cosimo Galletti, María Antonietta Barbieri, Francesco Ciodaro, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 4, pp. 630-630
Open Access | Times Cited: 24
Association Between T2-related Comorbidities and Effectiveness of Biologics in Severe Asthma
Michael E. Wechsler, Ghislaine Scélo, Désirée Larenas‐Linnemann, et al.
American Journal of Respiratory and Critical Care Medicine (2023) Vol. 209, Iss. 3, pp. 262-272
Open Access | Times Cited: 24
Efficacy and safety of dupilumab in the treatment of CRSwNP in the real-life setting: a review of the literature
Marella Reale, Giuseppe Licci, Pietro Orlando, et al.
European Archives of Oto-Rhino-Laryngology (2024) Vol. 281, Iss. 10, pp. 5023-5031
Closed Access | Times Cited: 9
Effect of Dupilumab in CRSwNP Sinonasal Outcomes from Real Life Studies: A Systematic Review with Meta-analysis
Miguel Rodriguez-Iglesias, Christian Calvo‐Henríquez, Daniel Martín-Jiménez, et al.
Current Allergy and Asthma Reports (2025) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Dupilumab (Dupixent®) tends to be an effective therapy for uncontrolled severe chronic rhinosinusitis with nasal polyps: real data of a single-centered, retrospective single-arm longitudinal study from a university hospital in Germany
Florian Jansen, Benjamin Becker, Jördis Kristin Eden, et al.
European Archives of Oto-Rhino-Laryngology (2022) Vol. 280, Iss. 4, pp. 1741-1755
Open Access | Times Cited: 31
Chronic rhinosinusitis with nasal polyps (CRSwNP) treated with omalizumab, dupilumab, or mepolizumab: A systematic review of the current knowledge towards an attempt to compare agents’ efficacy
George Papacharalampous, Jannis Constantinidis, G. Fotiadis, et al.
International Forum of Allergy & Rhinology (2023) Vol. 14, Iss. 1, pp. 96-109
Open Access | Times Cited: 21
Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience
Cosimo Galletti, Martina Ragusa, Federico Sireci, et al.
American Journal of Otolaryngology (2023) Vol. 45, Iss. 1, pp. 104106-104106
Open Access | Times Cited: 19
Biologics for Chronic Rhinosinusitis—A Modern Option for Therapy
Romică Cergan, Ovidiu Berghi, Mihai Dumitru, et al.
Life (2023) Vol. 13, Iss. 11, pp. 2165-2165
Open Access | Times Cited: 19
Biologic Therapies for Asthma and Allergic Disease: Past, Present, and Future
Fernando Ramírez-Jiménez, Gandhi F. Pavón-Romero, Juancarlos Manuel Velásquez-Rodríguez, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 270-270
Open Access | Times Cited: 17
Dupilumab efficacy in patients with chronic rhinosinusitis with nasal polyps with and without allergic rhinitis
Anju T. Peters, Martin Wagenmann, Jonathan A. Bernstein, et al.
Allergy and Asthma Proceedings (2023) Vol. 44, Iss. 4, pp. 265-274
Open Access | Times Cited: 17
Biologics for severe uncontrolled chronic rhinosinusitis with nasal polyps: a change management approach. Consensus of the Joint Committee of Italian Society of Otorhinolaryngology on biologics in rhinology
Eugenio De Corso, Gianluca Bellocchi, Michele De Benedetto, et al.
Acta Otorhinolaryngologica Italica (2021) Vol. 42, Iss. 1, pp. 1-16
Open Access | Times Cited: 33
Therapeutic Strategies of Biologics in Chronic Rhinosinusitis: Current Options and Future Targets
Junhu Tai, Mun Soo Han, Tae Hoon Kim
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 10, pp. 5523-5523
Open Access | Times Cited: 25
Biological Therapy of Severe Asthma and Nasal Polyps
Agamemnon Bakakos, Florence Schleich, Petros Bakakos
Journal of Personalized Medicine (2022) Vol. 12, Iss. 6, pp. 976-976
Open Access | Times Cited: 24
Quantitative CT Scan Imaging of the Airways for Diagnosis and Management of Lung Disease
Miranda Kirby, Benjamin M. Smith
CHEST Journal (2023) Vol. 164, Iss. 5, pp. 1150-1158
Closed Access | Times Cited: 14
Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
Claus Bachert, Tanya M. Laidlaw, Seong Cho, et al.
Annals of Otology Rhinology & Laryngology (2023) Vol. 132, Iss. 12, pp. 1649-1661
Open Access | Times Cited: 14
Dupilumab’s Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life
Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, et al.
Journal of Immunology Research (2023) Vol. 2023, pp. 1-10
Open Access | Times Cited: 13
The Role of Dupilumab in Severe Asthma
Fabio Luigi Massimo Ricciardolo, Francesca Bertolini, Vitina Carriero
Biomedicines (2021) Vol. 9, Iss. 9, pp. 1096-1096
Open Access | Times Cited: 31
Page 1 - Next Page

Scroll to top